N-Succinimidyl 3-(Bromoacetamido)propionate
Code | Size | Price |
---|
TAR-T16250-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T16250-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
N-Succinimidyl 3-(Bromoacetamido)propionate is a PEG-based PROTAC linker employed in the synthesis of PROTACs and antibody-drug conjugates (ADCs) [1, 2]. It acts as a cleavable ADC linker, facilitating the conjugation of drugs to antibodies for targeted delivery [2].
CAS:
57159-62-3
Formula:
C9H11BrN2O5
Molecular Weight:
307.1
Purity:
0.98
SMILES:
O=C(ON1C(=O)CCC1=O)CCNC(=O)CBr
References
Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.